ERGIC-53L Inhibitors
ERGIC-53L inhibitors are a diverse set of chemical compounds that target various stages of glycoprotein processing and trafficking, which are essential for the proper functioning of ERGIC-53L. Brefeldin A, Golgicide A, and Monensin, through their interactions with components of the vesicular transport system, induce potent disruptions in the ARF-dependent formation and maintenance of the ER-Golgi intermediate compartment, leading to a blockade of vesicle formation and trafficking. This directly impacts ERGIC-53L, as it is reliant on these processes for its activity. Similarly, Colchicine and Nocodazole perturb the microtubule network, which is critical for the transport of cargo proteins to the Golgi, and their inhibitory action indirectly suppresses ERGIC-53L function by stalling glycoprotein delivery. The inhibition of glycoprotein folding by Castanospermine, Tunicamycin, Swainsonine, Kifunensine, and Deoxynojirimycin adds another layer of functional control over ERGIC-53L. These compounds interfere with various enzymatic steps in the N-linked glycosylation pathway, leading to an accumulation of misfolded glycoproteins, which are substrates for ERGIC-53L, thus indirectly attenuating its activity.
The precision with which these inhibitors exert their effects on the biochemical pathways related to ERGIC-53L is mirrored by the specificity of their targets. Castanospermine, Tunicamycin, Swainsonine, and Kifunensine disrupt distinct steps in glycoprotein folding and maturation, consequently leading to the retention of glycoproteins in the ER and hampering ERGIC-53L's role in their trafficking. Deoxynojirimycin's inhibition of alpha-glucosidases I and II, Exo1's inhibition of the exocyst complex, and Ilimaquinone's disassembly of the Golgi apparatus demonstrate alternative mechanisms that converge on the indirect inhibition of ERGIC-53L. These inhibitors collectively destabilize the cellular architecture necessary for ERGIC-53L's functionality, either by causing unfolded glycoproteins to accumulate in the ER or by disrupting the Golgi structure itself, thus preventing ERGIC-53L from fulfilling its role in glycoprotein trafficking. Through these multifaceted inhibitory actions, the function of ERGIC-53L is effectively diminished, exemplifying the complex nature of intracellular trafficking and the precision required to modulate it.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), a small GTPase involved in vesicle formation in the ER-Golgi intermediate compartment (ERGIC). By inhibiting ARF, Brefeldin A disrupts the function of ERGIC-53L by preventing proper vesicle formation and trafficking. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is a sodium ionophore that disrupts Golgi function and pH gradient. Since ERGIC-53L is involved in glycoprotein trafficking from the ER to the Golgi, Monensin indirectly inhibits ERGIC-53L by collapsing the pH gradient necessary for its function. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is a glucosidase inhibitor that prevents proper glycoprotein folding in the ER, which is necessary for ERGIC-53L function. This inhibition results in the functional attenuation of ERGIC-53L due to the accumulation of misfolded glycoproteins. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation, a process vital for the proper function of ERGIC-53L. By preventing the initial step of glycosylation, it leads to the accumulation of glycoproteins in the ER, indirectly inhibiting the activity of ERGIC-53L. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine is an inhibitor of Golgi mannosidase II, which is required for the processing of N-glycans, substrates for ERGIC-53L. The inhibition of this enzyme disrupts the maturation of glycoproteins, thereby indirectly affecting the function of ERGIC-53L. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin, disrupting microtubule polymerization, which is essential for vesicle trafficking between the ER and the Golgi. This disruption leads to an indirect inhibition of ERGIC-53L function by impeding the transport of cargo proteins. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole is a microtubule-depolymerizing agent that, like Colchicine, affects vesicle transport between the ER and the Golgi. The resulting disruption of microtubules indirectly inhibits ERGIC-53L activity by hampering the proper trafficking of glycoproteins. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi brefeldin A resistance factor 1 (GBF1), a GEF for the ARF family of GTPases. By inhibiting GBF1, Golgicide A disrupts the function of ERGIC-53L by affecting ARF-mediated vesicle formation and maintenance of ERGIC structure and function. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase I inhibitor that leads to misprocessing of N-glycans in the ER, a necessary step for ERGIC-53L function. This inhibitor leads to the accumulation of improperly processed glycoproteins, indirectly reducing the function of ERGIC-53L. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits alpha-glucosidases I and II in the ER, which are critical for the proper folding of N-linked glycoproteins. This inhibition indirectly diminishes ERGIC-53L function by causing the retention of unfolded glycoproteins in the ER. | ||||||